Arcus Biosciences Inc (RCUS)
Debt-to-equity ratio
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 462,000 | 657,000 | 842,000 | 502,000 | 164,000 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2023 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $462,000K
= 0.00
The debt-to-equity ratio of Arcus Biosciences Inc has consistently been 0.00 over the past five years, indicating that the company has not had any financial leverage through debt during this period. This suggests that the company has primarily relied on equity financing to support its operations and growth. A debt-to-equity ratio of 0.00 typically indicates that the company's assets are funded entirely by shareholder equity, which may be viewed positively by investors and creditors as it implies lower financial risk. However, it is important to note that a low debt-to-equity ratio could also limit the company's ability to leverage debt for potential expansion or investment opportunities in the future.
Peer comparison
Dec 31, 2023